The FDA has announced the withdrawal of andexanet alfa, due to concerns that the risks of the product outweigh the benefits based on the results of the ANNEXA-I trial. Andexanet alfa was used for reversing the anticoagulant effect of factor Xa inhibitors, like apixaban and rivaroxaban, in patients with life-threatening or uncontrolled bleeding.

Read more here.